Marshall Wace, LLP Ultragenyx Pharmaceutical Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 334,078 shares of RARE stock, worth $13.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
334,078
Previous 1,051,573
68.23%
Holding current value
$13.8 Million
Previous $44.2 Million
72.66%
% of portfolio
0.02%
Previous 0.06%
Shares
18 transactions
Others Institutions Holding RARE
# of Institutions
337Shares Held
89.8MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$414 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$232 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$173 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$133 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$109 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.9B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...